Previous 10 | Next 10 |
ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), today announced that its Chief Medical Officer and Chi...
- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experi...
Summary GAB has outperformed equity CEF benchmarks over the past year. We like the fund for its differentiated exposure beyond S&P 500 companies including through some international stocks. The current premium to NAV is below the average over the past year suggesting a good entr...
Summary Bonds are back, offering the highest yields in over a decade. With an emphasis on a fixed income, my portfolio is positioned for weaker growth but stronger markets in 2023. Using an income-compounding approach, I can continue to grow my future income stream for retirement by...
Summary CLM has a yield of 18.92% (based on the declared distributions for the next 12 months). This is attractive if the distribution can be supported. I continue my series digging into CEFs beyond the yield with a look at CLM. The distribution for 2023 has been declared, and at $0...
Summary Closed-end funds are great income investments thanks to tax laws and tradition. Being required to pay out most of their taxable gains explains a lot about how CEFs act. CEFs can be great income investments. Co-produced with Beyond Saving. Introduction W...
Summary While many are predicting negative performance in the stock market in 2023, I am building an income stream for retirement that does not depend on a bull market to succeed. The concept of compound interest is important for income investors to understand and to help navigate volat...
Summary 2 out of 23 CEF sectors were positive on price and 2 out of 23 sectors were positive on NAV last week. VFL offers tender results. Why it pays to monitor your CEF holdings for corporate actions. Author's note: This article was released to CEF/ETF Income Laborato...
Summary Don't believe for one second that any fund that doesn't cut its distribution, particularly with an astronomical 23.5% NAV yield, deserves a high premium. Because despite having the worst NAV performance of any CEF this year, down -44.4%, the Gabelli Multimedia Fund (GGT), did NO...
Summary We share data on many of the biggest and most-popular big-yield CEFs. We have a special focus on Guggenheim's widely-popular Strategic Opportunities Fund (GOF), currently yielding over 13%, but trading at a large premium to its net asset value. We also review a popular lever...
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...